Jane Street Group LLC Buys Shares of 16,140 Myomo, Inc. (NYSEAMERICAN:MYO)

Jane Street Group LLC bought a new stake in Myomo, Inc. (NYSEAMERICAN:MYO) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,140 shares of the company’s stock, valued at approximately $65,000. Jane Street Group LLC owned about 0.05% of Myomo at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of MYO. Vontobel Holding Ltd. acquired a new position in shares of Myomo during the third quarter valued at about $90,000. AlphaCentric Advisors LLC bought a new stake in Myomo in the third quarter worth about $200,000. Stonepine Capital Management LLC bought a new position in Myomo during the third quarter valued at $401,000. GSA Capital Partners LLP increased its holdings in Myomo by 60.8% in the 3rd quarter. GSA Capital Partners LLP now owns 103,342 shares of the company’s stock worth $414,000 after acquiring an additional 39,085 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its position in shares of Myomo by 40.2% in the third quarter. Essex Investment Management Co. LLC now owns 899,135 shares of the company’s stock valued at $3,606,000 after purchasing an additional 257,749 shares during the period. 44.99% of the stock is owned by institutional investors.

Myomo Price Performance

Shares of NYSEAMERICAN MYO opened at $6.18 on Thursday. Myomo, Inc. has a 1 year low of $2.51 and a 1 year high of $7.17. The stock has a market cap of $186.95 million, a P/E ratio of -26.87 and a beta of 1.71.

Myomo (NYSEAMERICAN:MYO) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $9.21 million during the quarter, compared to analyst estimates of $7.95 million. Myomo had a negative net margin of 33.22% and a negative return on equity of 86.30%. As a group, research analysts forecast that Myomo, Inc. will post -0.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Ascendiant Capital Markets raised their target price on Myomo from $8.50 to $9.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and set a $7.50 price target on shares of Myomo in a research note on Wednesday, November 13th. Finally, Craig Hallum increased their price objective on Myomo from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 13th.

Myomo Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.